TY - JOUR
TI - IFN-β differentially regulates the function of T cell subsets in MS and EAE
AU - Kavrochorianou, N.
AU - Markogiannaki, M.
AU - Haralambous, S.
JO - Cytokine and Growth Factor Reviews
PY - 2016
VL - 30
TODO - null
SP - 47-54
PB - Elsevier Ireland Ltd
SN - 1359-6101
TODO - 10.1016/j.cytogfr.2016.03.013
TODO - beta interferon;  beta interferon, autoimmunity;  blood brain barrier;  CD4+ T lymphocyte;  cytokine production;  cytokine response;  enzyme regulation;  experimental autoimmune encephalomyelitis;  helper cell;  human;  immunomodulation;  in vitro study;  in vivo study;  lymphocyte subpopulation;  multiple sclerosis;  nonhuman;  pathogenesis;  priority journal;  protein expression;  protein function;  regulatory T lymphocyte;  Short Survey;  signal transduction;  T follicular helper cell;  T lymphocyte activation;  Th1 cell;  Th17 cell;  Th2 cell;  animal;  CD4+ T lymphocyte;  experimental autoimmune encephalomyelitis;  immunology;  multiple sclerosis;  T lymphocyte subpopulation, Animals;  CD4-Positive T-Lymphocytes;  Encephalomyelitis, Autoimmune, Experimental;  Humans;  Interferon-beta;  Multiple Sclerosis;  T-Lymphocyte Subsets
TODO - Multiple sclerosis (MS) is considered as a T cell mediated autoimmune disease of the CNS, although a pathogenic role has also been attributed to other immune cell types as well as to environmental and genetic factors. Considering that T cells are interesting from an immunopathogenic point of view and consequently from a therapeutic perspective, various T cell targeted therapies have been approved for MS. Interferon beta (IFN-β) is widely used as first-line intervention for modulating T cell responses, although its pleiotropic and multifaceted activities influence its effectiveness on the disease development, with mechanisms that are not yet fully understood. Since different T cell populations, including pro-inflammatory and regulatory T cells, might affect the course of MS, the effects of IFN-β become even more complex. This review will summarize recent findings regarding the T cell targeted effect of IFN-β in MS and its animal model EAE, with emphasis on the direct actions of endogenous and exogenous IFN-β on each T cell subpopulation involved in CNS autoimmunity. Delineating how IFN-β exerts its action on different T cell types may eventually contribute to the designing of therapeutic strategies aiming to improve the effectiveness of this drug for MS treatment. © 2016 Elsevier Ltd
ER -